Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
主要な著者: | Chakravarthy, U, Harding, S, Rogers, C, Downes, S, Lotery, A, Wordsworth, S, Reeves, B |
---|---|
フォーマット: | Journal article |
出版事項: |
2012
|
類似資料
-
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.
著者:: Chakravarthy, U, 等
出版事項: (2012) -
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial
著者:: Chakravarthy, U, 等
出版事項: (2012) -
Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.
著者:: Dakin, H, 等
出版事項: (2014) -
Bevacizumab versus ranibizumab for neovascular age-related macular degeneration:a Meta-analysis
著者:: Wen-Jie Wang, 等
出版事項: (2015-02-01) -
Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients
著者:: Zhe-Li Liu, 等
出版事項: (2013-04-01)